BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

591 related articles for article (PubMed ID: 31379815)

  • 1. The Complement Receptors C3aR and C5aR Are a New Class of Immune Checkpoint Receptor in Cancer Immunotherapy.
    Wang Y; Zhang H; He YW
    Front Immunol; 2019; 10():1574. PubMed ID: 31379815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autocrine Complement Inhibits IL10-Dependent T-cell-Mediated Antitumor Immunity to Promote Tumor Progression.
    Wang Y; Sun SN; Liu Q; Yu YY; Guo J; Wang K; Xing BC; Zheng QF; Campa MJ; Patz EF; Li SY; He YW
    Cancer Discov; 2016 Sep; 6(9):1022-35. PubMed ID: 27297552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absence of signaling into CD4⁺ cells via C3aR and C5aR enables autoinductive TGF-β1 signaling and induction of Foxp3⁺ regulatory T cells.
    Strainic MG; Shevach EM; An F; Lin F; Medof ME
    Nat Immunol; 2013 Feb; 14(2):162-71. PubMed ID: 23263555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune cell-derived C3a and C5a costimulate human T cell alloimmunity.
    Cravedi P; Leventhal J; Lakhani P; Ward SC; Donovan MJ; Heeger PS
    Am J Transplant; 2013 Oct; 13(10):2530-9. PubMed ID: 24033923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contribution of the anaphylatoxin receptors, C3aR and C5aR, to the pathogenesis of pulmonary fibrosis.
    Gu H; Fisher AJ; Mickler EA; Duerson F; Cummings OW; Peters-Golden M; Twigg HL; Woodruff TM; Wilkes DS; Vittal R
    FASEB J; 2016 Jun; 30(6):2336-50. PubMed ID: 26956419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting C3a/C5a receptors inhibits human mesangial cell proliferation and alleviates immunoglobulin A nephropathy in mice.
    Zhang Y; Yan X; Zhao T; Xu Q; Peng Q; Hu R; Quan S; Zhou Y; Xing G
    Clin Exp Immunol; 2017 Jul; 189(1):60-70. PubMed ID: 28295247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deficiency of Complement C3a and C5a Receptors Prevents Angiotensin II-Induced Hypertension via Regulatory T Cells.
    Chen XH; Ruan CC; Ge Q; Ma Y; Xu JZ; Zhang ZB; Lin JR; Chen DR; Zhu DL; Gao PJ
    Circ Res; 2018 Mar; 122(7):970-983. PubMed ID: 29437833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological targeting of anaphylatoxin receptors during the effector phase of allergic asthma suppresses airway hyperresponsiveness and airway inflammation.
    Baelder R; Fuchs B; Bautsch W; Zwirner J; Köhl J; Hoymann HG; Glaab T; Erpenbeck V; Krug N; Braun A
    J Immunol; 2005 Jan; 174(2):783-9. PubMed ID: 15634899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complementing T-cell Function: An Inhibitory Role of the Complement System in T-cell-Mediated Antitumor Immunity.
    Peng W; McKenzie JA; Hwu P
    Cancer Discov; 2016 Sep; 6(9):953-5. PubMed ID: 27587467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of the anaphylatoxin receptors, complement anaphylatoxin 3a receptor and complement anaphylatoxin 5a receptor, in the nasal mucosa of patients with mild and severe persistent allergic rhinitis.
    Jun SW; Kim TH; Lee HM; Lee SH; Kim WJ; Park SJ; Kim YS; Lee SH
    J Allergy Clin Immunol; 2008 Jul; 122(1):119-25. PubMed ID: 18538384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complement C3aR/C5aR-binding protein Suilysin of Streptococcus suis contributes to monocyte chemotaxis.
    Deng S; Zhao L; Zhu J; Chen L; Zhou R
    Vet Microbiol; 2020 Mar; 242():108599. PubMed ID: 32122603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ligand-induced phosphorylation of anaphylatoxin receptors C3aR and C5aR is mediated by "G protein-coupled receptor kinases.
    Langkabel P; Zwirner J; Oppermann M
    Eur J Immunol; 1999 Sep; 29(9):3035-46. PubMed ID: 10508278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of complement anaphylatoxin receptors (C3aR, C5aR) in the development of the rat cerebellum.
    Bénard M; Raoult E; Vaudry D; Leprince J; Falluel-Morel A; Gonzalez BJ; Galas L; Vaudry H; Fontaine M
    Mol Immunol; 2008 Aug; 45(14):3767-74. PubMed ID: 18635264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complement gene expression is regulated by pro-inflammatory cytokines and the anaphylatoxin C3a in human tenocytes.
    Busch C; Girke G; Kohl B; Stoll C; Lemke M; Krasnici S; Ertel W; Silawal S; John T; Schulze-Tanzil G
    Mol Immunol; 2013 Apr; 53(4):363-73. PubMed ID: 23070120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of C3a receptors, C5a receptors, and complement protein C6 deficiency in collagen antibody-induced arthritis in mice.
    Banda NK; Hyatt S; Antonioli AH; White JT; Glogowska M; Takahashi K; Merkel TJ; Stahl GL; Mueller-Ortiz S; Wetsel R; Arend WP; Holers VM
    J Immunol; 2012 Feb; 188(3):1469-78. PubMed ID: 22205026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Signaling through C5a receptor and C3a receptor diminishes function of murine natural regulatory T cells.
    Kwan WH; van der Touw W; Paz-Artal E; Li MO; Heeger PS
    J Exp Med; 2013 Feb; 210(2):257-68. PubMed ID: 23382542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blockade of C5a receptor unleashes tumor-associated macrophage antitumor response and enhances CXCL9-dependent CD8
    Luan X; Lei T; Fang J; Liu X; Fu H; Li Y; Chu W; Jiang P; Tong C; Qi H; Fu Y
    Mol Ther; 2024 Feb; 32(2):469-489. PubMed ID: 38098230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of C3a receptor expression on human leucocytes by the use of novel monoclonal antibodies.
    Zwirner J; Götze O; Begemann G; Kapp A; Kirchhoff K; Werfel T
    Immunology; 1999 May; 97(1):166-72. PubMed ID: 10447728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deletion of both the C3a and C5a receptors fails to protect against experimental autoimmune encephalomyelitis.
    Ramos TN; Wohler JE; Barnum SR
    Neurosci Lett; 2009 Dec; 467(3):234-6. PubMed ID: 19850104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complement C3a and C5a receptor blockade modulates regulatory T cell conversion in head and neck cancer.
    Gadwa J; Bickett TE; Darragh LB; Knitz MW; Bhatia S; Piper M; Van Court B; Bhuvane S; Nguyen D; Nangia V; Kleczko EK; Nemenoff RA; Karam SD
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33789881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.